Celiac Disease: From Genetic Risk to Disease Development
Celiac Disease: From Genetic Risk to Disease Development
批准号:
7591126
负责人:
Susan L. Neuhausen
金额:
$7.16万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2010-06-28
关键词:
Abdominal PainAddressAdherenceAgeAnemiaAntibodiesAtrophicAutoimmune DiseasesBarleyBiological MarkersCaliforniaCeliac DiseaseChildChronicClinicClinical ManagementCohort StudiesDataDevelopmentDiagnosisDiarrheaDietDietary ProteinsDiseaseEarly DiagnosisEmotional StressEnrollmentEuropeanEventFailureFamilyFamily StudyFamily memberFirst Degree RelativeFrequenciesGeneral PopulationGenetic RiskGlutenGrowthHealthHigh PrevalenceHistologicImmune System DiseasesIncidenceIndividualInfiltrationInsulin-Dependent Diabetes MellitusLifeLymphocyteLymphomaMalabsorption SyndromesMinorMorbidity - disease rateOperative Surgical ProceduresOsteoporosisParticipantPernicious AnemiaPharmacological TreatmentPopulationPregnancyPrevalencePrincipal InvestigatorPublic HealthQuestionnairesRecontactsRecurrenceReportingRheumatoid ArthritisRiskRye cerealSamplingScreening procedureSeizuresSerologic testsSerologicalSerumSmall IntestinesSpontaneous abortionStomachStressSymptomsTestingThyroiditisTimeTranslationsUniversitiesVillusVitamin DeficiencyWheatcohortflufollow-uphigh riskimprovedintestinal epitheliumpopulation basedpreventprograms
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Celiac disease (CD, gluten-sensitive enteropathy, celiac sprue) is a common disease with significant morbidity if untreated. It is caused by sensitivity to the dietary protein gluten, which is present in wheat, rye and barley. The term gluten-sensitive enteropathy refers to the histologic abnormality of the small intestine. It is now recognized to be a common disease, with reports that the disease frequency is 1:150 in the US, similar to European estimates. Before the development of highly specific and sensitive antibody tests, CD was under-diagnosed. Recently, it has been proposed that in addition to better diagnosis, CD is also increasing in incidence. Occult disease is frequently present with minimal classic symptoms or signs. The ratio of symptomatic to asymptomatic CD is estimated to be 1:7. Some complications of CD include lymphoma, osteoporosis, anemia, miscarriages, seizures, vitamin deficiencies, and co-occurrence of other autoimmune diseases. No pharmacological treatment is available. Although treatment with a gluten-free diet will improve symptoms, recurrence of symptoms and complications may occur after minor dietary indiscretions. There are several unaddressed public health concerns that will be focused on in this proposal. Do individuals at high risk of CD warrant continued screening and are there putative stress events that trigger the disease in susceptible individuals? Does the early detection of CD by screening reduce the risk of development of additional autoimmune disorders that are known to be associated with CD? Are individuals diagnosed with CD at higher risk of developing other autoimmune diseases and additional symptoms if they do not adhere to a gluten-free diet? To investigate these questions, we will recontact individuals previously enrolled in two family studies, one at the University of California Irvine and one at Mayo Clinic, in which we had systematically performed serologic and HLA testing and collected symptom data for family members from CD families. Aim 1 is to investigate the development of CD in first-degree relatives of CD cases who previously tested negative five or more years ago. We will perform serologic testing for CD and have the subjects complete a follow-up questionnaire including data items on general health, CD symptoms, associated-diseases, diet, and major life events as potential triggers for CD. Aim 2 is to investigate the prevalence of auto-antibodies that serve as biomarkers for thyroiditis, type I diabetes, pernicious anemia, and rheumatoid arthritis in CD cases. We will obtain new sera and follow-up questionnaires from CD cases diagnosed at least five years ago. This study will address two critical public health management issues in CD: 1) whether retesting is necessary for those at high-risk who have previously tested negative; and 2) whether the association of CD with other auto-immune diseases can be mitigated by following a gluten-free diet. These results will provide information to facilitate translation into clinical management of the disease and its comorbid conditions.This proposal is focused on the public health implications of celiac disease, a common disease with a population prevalence of 1:150 in the US. First, we will determine whether a single test for celiac disease in individuals at high risk of disease is adequate or whether repeat testing is necessary. Second, we will determine the impact of celiac disease on the development of other autoimmune diseases, and whether adherence to a gluten-free diet can prevent development, delay onset, or reduce symptoms of other auto-immune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort
-
批准号:10669253
-
项目类别:
-
资助金额:$65.67万
-
财政年份:2022
-
负责人:Susan L. Neuhausen
-
依托单位:
Environmental Chemical Body Burden and Prospective Breast Cancer Risk in the Cancer Prevention Study-3 Cohort
-
批准号:10525499
-
项目类别:
-
资助金额:$64.96万
-
财政年份:2022
-
负责人:Susan L. Neuhausen
-
依托单位:
Germline and Tumor Genomic Analyses of Breast Cancer in Latinas
-
批准号:8673705
-
项目类别:
-
资助金额:$90.96万
-
财政年份:2014
-
负责人:Susan L. Neuhausen
-
依托单位:
Celiac Disease: From Genetic Risk to Disease Development
-
批准号:8068619
-
项目类别:
-
资助金额:$15.27万
-
财政年份:2008
-
负责人:Susan L. Neuhausen
-
依托单位:
Celiac Disease: From Genetic Risk to Disease Development
-
批准号:7371748
-
项目类别:
-
资助金额:$20.15万
-
财政年份:2008
-
负责人:Susan L. Neuhausen
-
依托单位:
The IGF Signaling Pathway and Breast Cancer Risk
-
批准号:7579023
-
项目类别:
-
资助金额:$50.22万
-
财政年份:2007
-
负责人:Susan L. Neuhausen
-
依托单位:
The IGF Signaling Pathway and Breast Cancer Risk
-
批准号:7777345
-
项目类别:
-
资助金额:$51.85万
-
财政年份:2007
-
负责人:Susan L. Neuhausen
-
依托单位:
The IGF Signaling Pathway and Breast Cancer Risk
-
批准号:7373525
-
项目类别:
-
资助金额:$52.56万
-
财政年份:2007
-
负责人:Susan L. Neuhausen
-
依托单位:
The IGF Signaling Pathway and Breast Cancer Risk
-
批准号:7213798
-
项目类别:
-
资助金额:$56.0万
-
财政年份:2007
-
负责人:Susan L. Neuhausen
-
依托单位:
GENETIC EPIDEMIOLOGY OF BREAST CANCER--BRCA1 AND BRCA2
-
批准号:6164238
-
项目类别:
-
资助金额:$44.23万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Genetic Epidemiology of Breast Cancer: BRCA1 and BRCA2
-
批准号:6950052
-
项目类别:
-
资助金额:$56.15万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Genetic Epidemiology of Breast Cancer: BRCA1 and BRCA2
-
批准号:7286654
-
项目类别:
-
资助金额:$26.65万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
GENETIC EPIDEMIOLOGY OF BREAST CANCER--BRCA1 AND BRCA2
-
批准号:6362624
-
项目类别:
-
资助金额:$45.61万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
GENETIC EPIDEMIOLOGY OF BREAST CANCER--BRCA1 AND BRCA2
-
批准号:2469562
-
项目类别:
-
资助金额:$44.34万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
GENETIC EPIDEMIOLOGY OF BREAST CANCER--BRCA1 AND BRCA2
-
批准号:2882482
-
项目类别:
-
资助金额:$42.89万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Genetic Epidemiology of Breast Cancer: BRCA1 and BRCA2
-
批准号:6680035
-
项目类别:
-
资助金额:$54.53万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
GENETIC EPIDEMIOLOGY OF BREAST CANCER--BRCA1 AND BRCA2
-
批准号:6655490
-
项目类别:
-
资助金额:$31.67万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Genetic Epidemiology of Breast Cancer: BRCA1 and BRCA2
-
批准号:6801506
-
项目类别:
-
资助金额:$54.56万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Genetic Epidemiology of Breast Cancer: BRCA1 and BRCA2
-
批准号:7120490
-
项目类别:
-
资助金额:$56.18万
-
财政年份:1998
-
负责人:Susan L. Neuhausen
-
依托单位:
Cancer Control and Population Sciences
-
批准号:10059210
-
项目类别:
-
资助金额:$6.1万
-
财政年份:1997
-
负责人:Susan L. Neuhausen
-
依托单位:
海外基金